Recently, the Shanghai Municipal Commission of Economy and Informatization officially released the "2025 List of Shanghai Specialized and Sophisticated SMEs (Fourth Batch)". VKEY-BIO (Shanghai) Biotechnology Co., Ltd. was successfully selected and honored with the title "Shanghai Specialized and Sophisticated SME" due to its outstanding innovative capabilities and professional development level in the field of high-end domestic reagent R&D. This represents another authoritative recognition for VKEY-BIO, following honors such as "High-Tech Enterprise", "Innovative SME", and "Technology-based SME", marking a new stage in the company's development.
"Specialized and Sophisticated" is a significant national project aimed at guiding small and medium-sized enterprises towards specialized, refined, distinctive, and innovative development paths. The goal is to cultivate a group of high-quality enterprises with independent innovation capabilities, leadership in market segments, and mastery of key core technologies. According to the "Notice of the Shanghai Municipal Commission of Economy and Informativity on Organizing the 2025 Gradient Cultivation Work for Specialized and Sophisticated SMEs" (Hu Jing Xin Qi [2025] No. 15), following rigorous expert evaluation and comprehensive assessment, VKEY-BIO stood out among numerous applicant companies and successfully joined the ranks of Shanghai's specialized and sophisticated enterprises. A total of 3,861 companies in the city were selected for this fourth batch, with a validity period of three years requiring regular reviews, fully reflecting the authority and high value of this recognition.
Founded in 2019 and located in the Zhangjiang Hi-Tech Park in Shanghai, VKEY-BIO (Shanghai) Biotechnology Co., Ltd. is an enterprise dedicated to the R&D, production, and sales of high-end domestic reagents. Since its inception, the company has adhered to the development philosophy of "Innovation-driven, Quality-oriented". It has successively obtained honors such as "High-Tech Enterprise", "Innovative SME", and "Technology-based SME", and has passed the ISO9001 quality system certification, establishing a comprehensive quality management system. Leveraging solid professional capabilities and a rigorous, responsible service attitude, VKEY-BIO is committed to providing high-quality assay kits for the fields of drug discovery and life science exploration, helping customers reduce the cost of new drug R&D and accelerate the R&D process.
The company's products are primarily used in key stages such as early drug screening and validation, and preclinical research. The core proprietary technology platforms include:
I. KeyTec® Chemiluminescence Technology Platform:
The KeyTec® Luminescent series reagents feature higher sensitivity and longer half-lives, providing researchers with a range of solutions for cell viability assays, reporter gene assays, and in vivo small animal imaging studies.
II. KeyTec® TR-FRET Technology Platform:
This time-resolved fluorescence resonance energy transfer system, built on lanthanide-based fluorescent donors (Solar Eu/Tb, Bright Eu/Tb) and fluorescent acceptors (LA/HX, Green), offers advantages such as low background interference, low false positive rates, and high detection sensitivity. It is widely applied in fields including protein-protein interaction, enzyme research, GPCR pathways, tumor immunology, and antibody development.
III. TR-FLISA® Technology and KeyTec ALPHA® Technology Platform:
These platforms further enrich the company's technological matrix, providing customers with more diverse detection options.
These core technology platforms with independent intellectual property rights enable VKEY-BIO to establish a unique competitive advantage in the high-end reagent field, effectively breaking the monopoly of foreign brands in certain areas and providing cost-effective "domestic substitution" solutions for domestic biomedical R&D.
The company persists in continuous innovation, constantly improving its technical level and product quality. This recognition as a "Specialized and Sophisticated" enterprise is a comprehensive affirmation of VKEY-BIO's specialization, innovation capability, technical distinctiveness, and development potential. Becoming a Shanghai "Specialized and Sophisticated" enterprise means that VKEY-BIO will receive key support from municipal and district-level economic and information technology departments, including assistance in technological innovation, market development, financing services, and talent introduction, providing strong backing for the company's further growth and expansion.
Standing at a new starting point, VKEY-BIO (Shanghai) Biotechnology Co., Ltd. will take this opportunity to closely follow the national strategic direction, continue to increase R&D investment, deepen technological innovation, expand product application scenarios, and continuously enhance its ability to serve customers. Simultaneously, the company will actively fulfill its social responsibilities, promote the accessibility of high-end domestic reagents to more scientific research institutions and pharmaceutical companies, and contribute to the advancement of life science research and new drug development in China.
English
